Literature DB >> 18698497

Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis.

Y Yoshiga1, D Goto, S Segawa, Y Ohnishi, I Matsumoto, S Ito, A Tsutsumi, M Taniguchi, T Sumida.   

Abstract

Invariant natural killer T (iNKT) cells play a protective role in the development of certain autoimmune diseases. However, their precise role in the pathogenesis of autoimmune arthritis remains unclear. In this study, we examined the possible contribution of iNKT cells in collagen-induced arthritis (CIA) by using iNKT cell-deficient mice (Jalpha281-/- mice). CIA in these mice was markedly suppressed and interleukin (IL)-17 production was reduced in a native type II collagen (CII)-specific T cell response. Draining lymph nodes of CII-immunized Jalpha281-/- mice contained a significantly low number of IL-17-producing T helper cells. To determine whether iNKT cells produce IL-17, we measured IL-17 by enzyme-linked immunosorbent assay in iNKT cells stimulated with the ligand, alpha-galactosylceramide (alpha-GalCer). Notably, splenocytes from Jalpha281-/- mice stimulated in this way were negative for IL-17, whereas those from C57BL/6 mice produced IL-17. Immunostaining for IL-17 in iNKT cells confirmed intracellular staining of the protein. RT-PCR analysis showed that iNKT cells expressed retinoid-related orphan receptor gammaT and IL-23 receptor. Moreover, cell sorting demonstrated that NK1.1- iNKT cells were the main producers of IL-17 compared with NK1.1+ iNKT cells. IL-17 production by iNKT cells was induced by IL-23-dependent and -independent pathways, since iNKT produced IL-17 when stimulated with either IL-23 or alpha-GalCer alone. Our findings indicate that iNKT cells are producers and activators of IL-17 via IL-23- dependent and -independent pathways, suggesting that they are key cells in the pathogenesis of CIA through IL-17.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698497

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  45 in total

Review 1.  Harnessing invariant NKT cells in vaccination strategies.

Authors:  Vincenzo Cerundolo; Jonathan D Silk; S Hajar Masri; Mariolina Salio
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

Review 2.  Stages versus subsets: Invariant Natural Killer T cell lineage differentiation.

Authors:  Heather M Buechel; Martin H Stradner; Louise M D'Cruz
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

Review 3.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

4.  Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis.

Authors:  Poh-Yi Gan; Oliver M Steinmetz; Diana S Y Tan; Kim M O'Sullivan; Joshua D Ooi; Yoichiro Iwakura; A Richard Kitching; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 10.121

Review 5.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

Review 6.  IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear.

Authors:  Koen Venken; Dirk Elewaut
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

7.  In vivo activation of invariant natural killer T cells induces systemic and local alterations in T-cell subsets prior to preterm birth.

Authors:  N Gomez-Lopez; R Romero; M Arenas-Hernandez; G Schwenkel; D St Louis; S S Hassan; T N Mial
Journal:  Clin Exp Immunol       Date:  2017-05-10       Impact factor: 4.330

8.  Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients.

Authors:  T D Shi; J M Zhang; X F Wang; M Chen; H Sun; C B Chen; H Ren
Journal:  Clin Exp Med       Date:  2011-07-12       Impact factor: 3.984

9.  The transcription factor Th-POK negatively regulates Th17 differentiation in Vα14i NKT cells.

Authors:  Isaac Engel; Meng Zhao; Dietmar Kappes; Ichiro Taniuchi; Mitchell Kronenberg
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

10.  Anti-IL-17 therapy restricts and reverses late-term corneal allorejection.

Authors:  Xiao-Tang Yin; Stephanie Zobell; Jason G Jarosz; Patrick M Stuart
Journal:  J Immunol       Date:  2015-03-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.